Literature DB >> 21046286

Genetic susceptibility of methylenetetrahydrofolate reductase (MTHFR) gene C677T, A1298C, and G1793A polymorphisms with risk for bladder transitional cell carcinoma in men.

Mohammad Reza Safarinejad1, Nayyer Shafiei, Shiva Safarinejad.   

Abstract

We performed a case-control study of 158 bladder transitional cell carcinoma (TCC) cases and 316 controls to investigate the association between methylenetetrahydrofolate reductase (MTHFR) C677T, A1298G, and G1793A polymorphisms and bladder cancer susceptibility by polymerase chain reaction restriction fragment length polymorphism (PCR-RLFP) technique. The controls were frequency-matched to the cases by age (± 5 years), ethnicity, and smoking status. We also measured serum levels of total homocysteine (tHcy), folate, and vitamin B12. It was found that the 1298AC (odds ratio, OR = 3.74; 95% confidence interval, CI = 2.34-5.47; P = 0.001) and 1298CC (OR = 3.46, 95% CI = 2.37-5.52; P = 0.001) genotypes of MTHFR A1298C were significantly associated with increased risk of bladder TCC. The MTHFR C677T and G1793A polymorphisms were not associated with bladder TCC. After stratification for grade and stage, we observed that the 677TT (OR = 4.47, 95% CI = 2.74-6.72; P = 0.001) and MTHFR 1298CC (OR = 4.78, 95% CI = 2.82-6.89; P = 0.001) genotypes of MTHFR were associated with increased risk of muscle-invasive bladder TCC. We also found that the MTHFR 677CT+1298AA genotypes were associated with an approximately 70% reduction in risk of bladder cancer (OR = 0.31; 95% CI = 0.15-0.68) compared to the combined referent genotype. There were 8 haplotypes and 16 haplotype genotypes based on these three variants. When we used the haplotypes and assumed that the 677T, 1298C, and 1793G alleles were risk alleles, the adjusted odds ratios increased as the number of risk alleles increased: 1.00 for 0-1 variant, 1.88 (1.4-2.7) for any two risk alleles and 2.07 (1.6-2.8) for any three risk alleles. Serum tHcy levels were significantly higher in carriers of the 677T, 1298C, and 1793G alleles compared to noncarriers (all P < 0.01). There was no significant correlation between serum levels of tHcy and folate and bladder cancer risk. Further studies in larger samples size and different ethnicity are required to confirm our findings.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21046286     DOI: 10.1007/s12032-010-9723-9

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  41 in total

1.  Food, nutrient and heterocyclic amine intake and the risk of bladder cancer.

Authors:  Reina García-Closas; Montserrat García-Closas; Manolis Kogevinas; Núria Malats; Debra Silverman; Consol Serra; Adonina Tardón; Alfredo Carrato; Gemma Castaño-Vinyals; Mustafa Dosemeci; Lee Moore; Nathaniel Rothman; Rashmi Sinha
Journal:  Eur J Cancer       Date:  2007-06-26       Impact factor: 9.162

2.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

Review 3.  Epidemiology and etiology of premalignant and malignant urothelial changes.

Authors:  S M Cohen; T Shirai; G Steineck
Journal:  Scand J Urol Nephrol Suppl       Date:  2000

4.  A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?

Authors:  N M van der Put; F Gabreëls; E M Stevens; J A Smeitink; F J Trijbels; T K Eskes; L P van den Heuvel; H J Blom
Journal:  Am J Hum Genet       Date:  1998-05       Impact factor: 11.025

5.  The effect of 677C-->T and 1298A-->C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects.

Authors:  A Chango; F Boisson; F Barbé; D Quilliot; S Droesch; M Pfister; N Fillon-Emery; D Lambert; S Frémont; D S Rosenblatt; J P Nicolas
Journal:  Br J Nutr       Date:  2000-06       Impact factor: 3.718

6.  A common variant of the methylenetetrahydrofolate reductase gene (1p36) is associated with an increased risk of cancer.

Authors:  Bastiaan T Heijmans; Jolanda M A Boer; H Eka D Suchiman; Cees J Cornelisse; Rudi G J Westendorp; Daan Kromhout; Edith J M Feskens; P Eline Slagboom
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

7.  A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity.

Authors:  I Weisberg; P Tran; B Christensen; S Sibani; R Rozen
Journal:  Mol Genet Metab       Date:  1998-07       Impact factor: 4.797

8.  Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients.

Authors:  Jiazhong Sun; Yancheng Xu; Yilian Zhu; Hongyun Lu
Journal:  Diabetes Res Clin Pract       Date:  2004-06       Impact factor: 5.602

9.  Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations.

Authors:  P F Jacques; A G Bostom; R R Williams; R C Ellison; J H Eckfeldt; I H Rosenberg; J Selhub; R Rozen
Journal:  Circulation       Date:  1996-01-01       Impact factor: 29.690

10.  Genetic, dietary, and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and women in Singapore.

Authors:  S M Saw; J M Yuan; C N Ong; K Arakawa; H P Lee; G A Coetzee; M C Yu
Journal:  Am J Clin Nutr       Date:  2001-02       Impact factor: 7.045

View more
  12 in total

Review 1.  Association between MTHFR Ala222Val (rs1801133) polymorphism and bladder cancer susceptibility: a systematic review and meta-analysis.

Authors:  Kai Li; Yong ping Hu; Zecheng Yang; Tongxin Sun
Journal:  Tumour Biol       Date:  2013-05-07

Review 2.  A literature review of MTHFR (C677T and A1298C polymorphisms) and cancer risk.

Authors:  Muzeyyen Izmirli
Journal:  Mol Biol Rep       Date:  2012-10-19       Impact factor: 2.316

3.  Genetic variation in glutathione S-transferase omega-1, arsenic methyltransferase and methylene-tetrahydrofolate reductase, arsenic exposure and bladder cancer: a case-control study.

Authors:  Jennifer L Beebe-Dimmer; Priyanka T Iyer; Jerome O Nriagu; Greg R Keele; Shilpin Mehta; Jaymie R Meliker; Ethan M Lange; Ann G Schwartz; Kimberly A Zuhlke; David Schottenfeld; Kathleen A Cooney
Journal:  Environ Health       Date:  2012-06-29       Impact factor: 5.984

4.  Elevated homocysteine level and folate deficiency associated with increased overall risk of carcinogenesis: meta-analysis of 83 case-control studies involving 35,758 individuals.

Authors:  Donghong Zhang; Xuemei Wen; Wei Wu; Ye Guo; Wei Cui
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

5.  Combined Genetic Biomarkers Confer Susceptibility to Risk of Urothelial Bladder Carcinoma in a Saudi Population.

Authors:  Nasser Attia Elhawary; Anmar Nassir; Hesham Saada; Anas Dannoun; Omar Qoqandi; Ammar Alsharif; Mohammed Taher Tayeb
Journal:  Dis Markers       Date:  2017-02-27       Impact factor: 3.434

6.  Association between methylenetetrahydrofolate reductase gene rs1801131 A/C polymorphism and urinary tumors' susceptibility.

Authors:  Shuaili Xu; Li Zuo
Journal:  Hereditas       Date:  2020-04-27       Impact factor: 3.271

Review 7.  Genetic and molecular biology of bladder cancer among Iranian patients.

Authors:  Majid Mojarrad; Meysam Moghbeli
Journal:  Mol Genet Genomic Med       Date:  2020-04-06       Impact factor: 2.183

Review 8.  Quantitative assessment of the association between MHTFR C677T (rs1801133, Ala222Val) polymorphism and susceptibility to bladder cancer.

Authors:  Wei Xu; Haifeng Zhang; Fa Wang; Honghui Wang
Journal:  Diagn Pathol       Date:  2013-06-17       Impact factor: 2.644

9.  Lack of association between MTHFR Ala222Val and Glu429Ala polymorphisms and bladder cancer risk: A meta-analysis of case-control studies.

Authors:  Rong Shi; Zhen Zhao; Hui Zhou; Jueyu Zhou; Wanlong Tan
Journal:  Biomed Rep       Date:  2014-03-19

10.  Correlations of MTHFR 677C>T polymorphism with cardiovascular disease in patients with end-stage renal disease: a meta-analysis.

Authors:  Xian-Hui Gao; Guo-Yi Zhang; Ying Wang; Hui-Ying Zhang
Journal:  PLoS One       Date:  2014-07-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.